Posts

Tenaya Therapeutics Partners with Alnylam in $1.13B Cardiovascular Gene Target Collaboration

on
Tenaya Therapeutics (NASDAQ: TNYA) announced a research collaboration with Alnylam Pharmaceuticals (NASDAQ: ALNY) on March 5, 2026, to identify and validate up to 15 gene targets for cardiovascular diseases. 1 2 3 Tenaya will receive up to $10 million in upfront payments, plus reimbursement for costs over a two-year validation term, and potential milestone payments totaling up to $1.13 billion if targets lead to approved therapeutics. 1 2 3 5 Alnylam will handle all development and commercialization of therapeutics from the validated targets. 1 2 3 The deal combines Tenaya's target identification and validation expertise with Alnylam's RNAi therapeutics leadership to advance potential disease-modifying heart treatments. 1 2 4 Sources: 1. https://www.stocktitan.net/news/TNYA/tenaya-therapeutics-enters-into-research-collaboration-with-alnylam-br4m7y44cga4.html 2. https://www.biospace.com/deals/alnylam-unites-with-tenaya-in-potential-1b-pact-to-find-new-genetic-heart...

Eli Lilly Launches Employer Connect Platform to Expand GLP-1 Obesity Drug Access

on

Zealand Pharma and Roche's Obesity Drug Development and Clinical Progress

on

FDA Rejects UniQure's AMT-130 Gene Therapy Data for Huntington's, Demands New Sham-Controlled Trial

on

Advita Ortho Announces Key Executive Leadership Appointments

on

Merck KGaA Discontinues Two Cancer Drug Trials After Failures

on

Yale's Craig Crews Builds Model to Guide Biotech Startups Out of Academia's 'Valley of Death'

on

FDA's PreCheck Pilot Program: Aligning on Regulatory Pathways to Avoid Approval Surprises

on

Theravance Biopharma Halves Workforce and Ends R&D After Phase 3 Failure

on

Spotlight On #HTGS26: Agentic AI and Digital Endpoints Supercharging R&D

on

Esperion Therapeutics Acquires Corstasis for $75M Upfront to Gain Enbumyst Nasal Spray for Edema

on

Hims Pharmacy Partner Plans to Reintroduce GLP-1 Pill Pulled from Market Amid Regulatory Backlash

on

Moderna Agrees to Pay Up to $2.25 Billion to Settle COVID-19 Vaccine Patent Dispute with Arbutus and Roivant Subsidiary Genevant

on